142 related articles for article (PubMed ID: 17408102)
1. [Thalidomide-associated bradycardia in patients with hematologic diseases: a single institution experience].
López-de la Cruz I; Aguayo-González A; López-Karpovitch X
Rev Invest Clin; 2006; 58(5):424-31. PubMed ID: 17408102
[TBL] [Abstract][Full Text] [Related]
2. Syncope and sinus bradycardia from combined use of thalidomide and beta-blocker.
Yamaguchi T
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):1033-5. PubMed ID: 18613249
[TBL] [Abstract][Full Text] [Related]
3. [Thalidomide in oncological and hematological diseases].
Kivivuori SM; Anttila P
Duodecim; 2010; 126(12):1413-9. PubMed ID: 20617746
[TBL] [Abstract][Full Text] [Related]
4. Bradycardia during therapy for multiple myeloma with thalidomide.
Fahdi IE; Gaddam V; Saucedo JF; Kishan CV; Vyas K; Deneke MG; Razek H; Thorn B; Bissett JK; Anaissie EJ; Barlogie B; Mehta JL
Am J Cardiol; 2004 Apr; 93(8):1052-5. PubMed ID: 15081457
[TBL] [Abstract][Full Text] [Related]
5. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
[TBL] [Abstract][Full Text] [Related]
6. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
[TBL] [Abstract][Full Text] [Related]
8. Two cases of bacterial meningitis accompanied by thalidomide therapy in patients with multiple myeloma: is thalidomide associated with bacterial meningitis?
Pasa S; Altintas A; Cil T; Ustun C; Bayan K; Danis R; Urakci Z; Tuzun Y; Ayyildiz O
Int J Infect Dis; 2009 Jan; 13(1):e19-22. PubMed ID: 18621563
[TBL] [Abstract][Full Text] [Related]
9. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
10. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
Smith SM; Grinblatt D; Johnson JL; Niedzwiecki D; Rizzieri D; Bartlett NL; Cheson BD;
Br J Haematol; 2008 Feb; 140(3):313-9. PubMed ID: 18217897
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer.
Buttin BM; Moore MJ
Gynecol Oncol; 2008 Dec; 111(3):546-8. PubMed ID: 18191185
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
14. Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide.
Bauditz J; Lochs H; Voderholzer W
Endoscopy; 2006 Oct; 38(10):1036-9. PubMed ID: 17058171
[TBL] [Abstract][Full Text] [Related]
15. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
[No Abstract] [Full Text] [Related]
17. [Interstitial pneumonitis as an adverse effect of thalidomide].
Scholte JB; Potjewijd J; Voogt PJ; Custers FL; Lie KS
Ned Tijdschr Geneeskd; 2009; 153():A452. PubMed ID: 19785872
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.
Tamburini J; Elie C; Park S; Beyne-Rauzy O; Gardembas M; Berthou C; Mahe B; Sanhes L; Stamatoullas A; Vey N; Aouba A; Slama B; Quesnel B; Vekhoff A; Sotto JJ; Vassilief D; Al-Nawakil C; Fenaux P; Dreyfus F; Bouscary D;
Leuk Res; 2009 Apr; 33(4):547-50. PubMed ID: 18640718
[No Abstract] [Full Text] [Related]
19. Thalidomide-induced sinus bradycardia.
Kaur A; Yu SS; Lee AJ; Chiao TB
Ann Pharmacother; 2003; 37(7-8):1040-3. PubMed ID: 12841816
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
